List of Figures
Figure 1: Women’s Health, US, Innovation Trends in Product Approvals, 1987–2014 7
Figure 2: Women’s Health, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 9
Figure 3: Women’s Health, Global, Market by Molecule Type, 2018 24
Figure 4: Women’s Health, Global, Market by Molecular Target, 2018 25
Figure 5: Women’s Health, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 26
Figure 6: Women’s Health, Global, Pipeline by Stage of Development and Molecule Type, 2018 27
Figure 7: Women’s Health, Global, Key Indications by Stage of Development, 2018 28
Figure 8: Women’s Health, Global, Key Indications by Molecule Type, 2018 29
Figure 9: Women’s Health, Global, Pipeline by Molecular Target, 2018 30
Figure 10: Women’s Health, Global, Breakdown of Key Molecular Target Classes, 2018 31
Figure 11: Women’s Health, Global, Key Indications by Molecular Target Class, 2018 32
Figure 12: Women’s Health, Global, Pipeline and Marketed Products by Molecular Target Class, 2018 33
Figure 13: Women’s Health, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2018 34
Figure 14: Women’s Health, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018 35
Figure 15: Women’s Health, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 36
Figure 16: Women’s Health, Global, List of All Pipeline Products, 2018 (part 1) 37
Figure 17: Women’s Health, Global, List of All Pipeline Products, 2018 (part 2) 38
Figure 18: Women’s Health, Global, List of All Pipeline Products, 2018 (part 3) 39
Figure 19: Women’s Health, Global, List of All Pipeline Products, 2018 (part 4) 40
Figure 20: Women’s Health, Global, List of All Pipeline Products, 2018 (part 5) 41
Figure 21: Women’s Health, Global, List of All Pipeline Products, 2018 (part 6) 42
Figure 22: Women’s Health, Global, List of All Pipeline Products, 2018 (part 7) 43
Figure 23: Women’s Health, Global, List of All Pipeline Products, 2018 (part 8) 44
Figure 24: Women’s Health, Global, List of All Pipeline Products, 2018 (part 9) 44
Figure 25: Women’s Health, Global, List of All Pipeline Products, 2018 (part 10) 45
Figure 26: Women’s Health, Global, First-in-Class Matrix Assessment for Endometriosis, 2018 48
Figure 27: Women’s Health, Global, First-in-Class Matrix Assessment for PCOS, 2018 48
Figure 28: Women’s Health, Global, First-in-Class Matrix Assessment for CIN (Human Proteins), 2018 48
Figure 29: Women’s Health, Global, First-in-Class Matrix Assessment for CIN (Viral Proteins), 2018 49
Figure 30: Women’s Health, Global, All First-in-Class Molecular Targets Across the Women’s Health Pipeline, 2018 49
Figure 31: Women’s Health, Global, Industry-Wide Licensing Deals by Stage of Development and First-in-Class Product Status, 2006–2015 65
Figure 32: Women’s Health, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Product Status ($m), 2006–2015 66
Figure 33: Women’s Health, Global, Licensing Deals by Region, Value and Year, 2018 67
Figure 34: Women’s Health, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2018 68
Figure 35: Women’s Health, Global, Licensing Deals by Molecule Type, Molecular Target and Aggregate Deal Value, 2018 69
Figure 36: Women’s Health, Global, Licensing Deals with Disclosed Deal Values, 2018 (part 1) 70
Figure 37: Women’s Health, Global, Licensing Deals with Disclosed Deal Values, 2018 (part 2) 71
Figure 38: Women’s Health, Global, Co-development Deals by Region, Value and Year, 2018 72
Figure 39: Women’s Health, Global, Licensing Deals by Region, Value and Year, 2018 73
Figure 40: Women’s Health, Global, Licensing Deals by Region, Value and Year, 2018 73
Figure 41: Women’s Health, Global, Co-development with Disclosed Deal Values, 2018 74
Figure 42: Women’s Health, Global, First-in-Class Products with and without Prior Involvement in Licensing and Co-development Deals, 2018 (part 1) 75
Figure 43: Women’s Health, Global, First-in-Class Products with and without Prior Involvement in Licensing and Co-development Deals, 2018 (part 2) 76